Different effects of abciximab and cytochalasin D on clot strength in thrombelastography

Authors

  • T. Lang,

    1. Clinical Institute of Medical and Chemical Laboratory Diagnostics, * Department of Anesthesiology and Intensive Care Medicine and †Department of Surgery, Division of Biomedical Engineering and Computing, Karl-Franzens University School of Medicine, Graz, Austria
    Search for more papers by this author
  • W. Toller,

    1. Clinical Institute of Medical and Chemical Laboratory Diagnostics, * Department of Anesthesiology and Intensive Care Medicine and †Department of Surgery, Division of Biomedical Engineering and Computing, Karl-Franzens University School of Medicine, Graz, Austria
    Search for more papers by this author
  • M. Gütl,

    1. Clinical Institute of Medical and Chemical Laboratory Diagnostics, * Department of Anesthesiology and Intensive Care Medicine and †Department of Surgery, Division of Biomedical Engineering and Computing, Karl-Franzens University School of Medicine, Graz, Austria
    Search for more papers by this author
  • E. Mahla,

    1. Clinical Institute of Medical and Chemical Laboratory Diagnostics, * Department of Anesthesiology and Intensive Care Medicine and †Department of Surgery, Division of Biomedical Engineering and Computing, Karl-Franzens University School of Medicine, Graz, Austria
    Search for more papers by this author
  • H. Metzler,

    1. Clinical Institute of Medical and Chemical Laboratory Diagnostics, * Department of Anesthesiology and Intensive Care Medicine and †Department of Surgery, Division of Biomedical Engineering and Computing, Karl-Franzens University School of Medicine, Graz, Austria
    Search for more papers by this author
  • P. Rehak,

    1. Clinical Institute of Medical and Chemical Laboratory Diagnostics, * Department of Anesthesiology and Intensive Care Medicine and †Department of Surgery, Division of Biomedical Engineering and Computing, Karl-Franzens University School of Medicine, Graz, Austria
    Search for more papers by this author
  • W. März,

    1. Clinical Institute of Medical and Chemical Laboratory Diagnostics, * Department of Anesthesiology and Intensive Care Medicine and †Department of Surgery, Division of Biomedical Engineering and Computing, Karl-Franzens University School of Medicine, Graz, Austria
    Search for more papers by this author
  • G. Halwachs-Baumann

    1. Clinical Institute of Medical and Chemical Laboratory Diagnostics, * Department of Anesthesiology and Intensive Care Medicine and †Department of Surgery, Division of Biomedical Engineering and Computing, Karl-Franzens University School of Medicine, Graz, Austria
    Search for more papers by this author

Thomas H. Lang, Clinical Institute of Medical and Chemical Laboratory Diagnostics, Karl-Franzens University School of Medicine, Auenbruggerplatz 29, A-8036 Graz, Austria.
Tel.: +43 31 6385 7682; fax: +43 31 6385 3430; e-mail: thomas.lang@klinikum-graz.at

Abstract

Summary.  Maximum amplitude (MA) in thrombelastography (TEG) consists of a plasmatic and a platelet component. To assess the magnitude of the plasmatic component, pharmacological approaches have been proposed to eliminate the platelet component. We evaluated the individual and combined effects of abciximab and cytochalasin D on the MA of TEG. Whole blood, platelet-rich plasma (PRP) and homologous platelet-poor plasma (PPP) from 20 healthy volunteers were spiked with abciximab or cytochalasin D or a combination of both and TEGs performed. Abciximab and cytochalasin D decreased MA in all samples. MA of whole blood (18.6 ± 3.1 mm) and PRP (33.7 ± 3.5 mm) spiked with abciximab or cytochalasin D alone (15.0 ± 2.9 mm and 25.0 ± 4.0 mm) were significantly higher when compared with abciximab and cytochalasin D combined (10.4 ± 3.0 and 20.2 ± 3.5 mm). While MA of PRP and homologous PPP were significantly (P < 0.001) different after individual administration of abciximab and cytochalasin D, combination of both abolished this difference (20.2 ± 3.5 mm and 20.4 ± 3.7 mm, P = 0.372). In whole blood of critically ill patients or patients undergoing major surgery there was also a significant difference of MA between abciximab alone and in combination with cytochalasin D (16.5 ± 11.3 mm and 11.3 ± 7.7 mm, P < 0.001). This indicates that in contrast to individual administration of abciximab or cytochalasin D, a combination of both compounds eliminates the platelet-specific effect on MA of TEG tracings.

Ancillary